Breaking News Instant updates and real-time market news.

RGNX

Regenxbio

$37.50

0.27 (0.73%)

, ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24

Regenxbio upgraded to Market Perform on valuation at SVB Leerink

As previously reported, SVB Leerink analyst Mani Foroohar upgraded Regenxbio (RGNX) to Market Perform from Underperform, with a $37 price target, despite long-term headwinds. The analyst believes the current valuation balances the challenges of the company's partnership strategy and early-stage gene therapy pipeline with attractive anticipated royalty streams from Zolgensma and the competitive risk from Adverum Biotechnologies (ADVM) in wet AMD well-appreciated by investors. Nonetheless, Foroohar continues to have reservations about the long-term outlook for the company - intellectual property from the NAV platform has a finite lifetime, which self-limits royalty streams and exposes the company to litigation risk. As core patents approach expiry, the rate of new partnerships should continue to decrease, he adds.

RGNX

Regenxbio

$37.50

0.27 (0.73%)

ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

  • 09

    Sep

  • 11

    Sep

RGNX Regenxbio
$37.50

0.27 (0.73%)

05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.
06/05/19
CHDN
06/05/19
NO CHANGE
Target $145
CHDN
Buy
Regenxbio price target raised to $145 from $127 at Chardan
Chardan analyst Gbola Amusa raised his price target for Regenxbio to $145 from $127 ahead of profitability in 2020 on Zolgensma. Amusa notes that analysts are "unwilling" to model Regenxbio's portfolio of 5 internal and 25 external programs, and reiterates a Buy rating on the shares.
06/13/19
RAJA
06/13/19
INITIATION
Target $60
RAJA
Outperform
Regenxbio resumed with an Outperform at Raymond James
Raymond James analyst Dane Leone resumed Regenxbio with an Outperform rating and a price target of $60.
08/20/19
LEER
08/20/19
UPGRADE
LEER
Market Perform
Regenxbio upgraded to Market Perform from Underperform at SVB Leerink
SVB Leerink analyst Mani Foroohar upgraded Regenxbio to Market Perform from Underperform with a $37 price target.
ADVM Adverum Biotechnologies
$12.91

-0.5 (-3.73%)

05/17/19
PIPR
05/17/19
NO CHANGE
Target $12
PIPR
Overweight
Adverum Biotechnologies price target raised to $12 from $8 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Adverum Biotechnologies to $12 from $8 citing the positive ADVM-022 efficacy update. The analyst applauds management saying the ADVM-022 clinical hold was effectively lifted in just over a month. Further, management provided "some very bullish comments" by describing the ongoing results as "exciting" and demonstrating a "robust preliminary anatomical response" and "the potential to provide sustained efficacy following a single intravitreal injection," Van Buren tells investors in a research note. As such, he believes "impressive" reductions in central retinal thickness must have already been observed. The analyst maintains an Overweight rating on Adverum shares.
06/13/19
RAJA
06/13/19
INITIATION
RAJA
Market Perform
Adverum Biotechnologies resumed with a Market Perform at Raymond James
Raymond James analyst Dane Leone resumed Adverum Biotechnologies with a Market Perform rating.
07/29/19
RHCO
07/29/19
NO CHANGE
Target $12
RHCO
Hold
Adverum Biotechnologies price target raised to $12 from $4 at SunTrust
SunTrust analyst Joon Lee raised his price target on Adverum Biotechnologies to $12 after holding a call with its management about its ongoing trial of ADVM-02 in wet age-related macular degeneration, or wAMD. The analyst says he is including the program in his valuation given its recent progress, even though the longer-term safety issues remain an "overhang". Lee keeps his Hold rating on the stock given the "very high" hurdle for safety in wAMD gene therapy.
08/14/19
PIPR
08/14/19
NO CHANGE
Target $14
PIPR
Overweight
Piper confident in upcoming Adverum data after management meetings
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating on Adverum Biotechnologies with a $14 price target following meetings with management. The analyst expects to see preliminary 24-week results from the "all-important" Phase I Optic study of ADVM-022 on September 12. The results could provide proof of concept for the first intravitreal approach for the eye, "which would be monumental," Van Buren tells investors in a research note. He continues to have a "high level of confidence" in the data following his meetings with management.

TODAY'S FREE FLY STORIES

ABT

Abbott

$84.25

-0.96 (-1.13%)

, ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

13:22
09/14/19
09/14
13:22
09/14/19
13:22
Conference/Events
William Blair diagnostic products/med tech analyst to hold a group luncheon »

Diagnostic Products &…

ABT

Abbott

$84.25

-0.96 (-1.13%)

ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

BDX

Becton Dickinson

$260.68

-1.41 (-0.54%)

COO

Cooper Companies

$301.95

-3 (-0.98%)

EXAS

Exact Sciences

$106.72

-1.99 (-1.83%)

GH

Guardant Health

$77.54

0.49 (0.64%)

NEO

NeoGenomics

$21.34

-1.22 (-5.41%)

LMNX

Luminex

$22.62

0.1 (0.44%)

HAE

Haemonetics

$125.55

-0.31 (-0.25%)

STAA

STAAR Surgical

$29.21

0.415 (1.44%)

QGEN

Qiagen

$33.97

-0.105 (-0.31%)

NVTA

Invitae

$21.70

-0.2 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 13

    Nov

  • 05

    Dec

CRTO

Criteo

, TWTR

Twitter

13:19
09/14/19
09/14
13:19
09/14/19
13:19
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Technology & Internet…

CRTO

Criteo

TWTR

Twitter

SNAP

Snap

GOOGL

Alphabet Class A

FB

Facebook

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

T

AT&T

$37.90

-0.46 (-1.20%)

09:06
09/14/19
09/14
09:06
09/14/19
09:06
Periodicals
AT&T stock already benefiting from activist involvement, Barron's says »

AT&T 's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

DIS

Disney

$138.00

0.44 (0.32%)

, NFLX

Netflix

$294.00

5.08 (1.76%)

09:04
09/14/19
09/14
09:04
09/14/19
09:04
Periodicals
Consumers might not be as in love with Apple TV+ as Wall Street, Barron's says »

Following Apple's…

DIS

Disney

$138.00

0.44 (0.32%)

NFLX

Netflix

$294.00

5.08 (1.76%)

AAPL

Apple

$218.71

-4.4 (-1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Oct

UAL

United Airlines

$91.37

1.99 (2.23%)

08:58
09/14/19
09/14
08:58
09/14/19
08:58
Periodicals
United Airlines could get boost after short squeeze, Barron's says »

United Airlines stock has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BAC

Bank of America

$30.12

0.44 (1.48%)

08:55
09/14/19
09/14
08:55
09/14/19
08:55
Periodicals
Bank of America stock worth betting on, Barron's says »

Amid talk of a coming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TPR

Tapestry

$25.16

-0.43 (-1.68%)

08:49
09/14/19
09/14
08:49
09/14/19
08:49
Periodicals
Coach parent's turnaround could be coming, Barron's says »

Even in a rough year for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$379.63

4.21 (1.12%)

08:45
09/14/19
09/14
08:45
09/14/19
08:45
Periodicals
U-Haul parent stock 'a better-kept secret,' Barron's says »

Amerco (UHAL), owner of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

, CNI

Canadian National

$92.13

-0.31 (-0.34%)

08:41
09/14/19
09/14
08:41
09/14/19
08:41
Periodicals
Railroad stocks struggling as challenges increase, Barron's says »

North American railroads…

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

CNI

Canadian National

$92.13

-0.31 (-0.34%)

UNP

Union Pacific

$171.49

3.81 (2.27%)

CSX

CSX

$72.50

0.96 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

MO

Altria Group

$42.01

-0.77 (-1.80%)

, BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

08:06
09/14/19
09/14
08:06
09/14/19
08:06
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

MO

Altria Group

$42.01

-0.77 (-1.80%)

BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$73.01

-1.89 (-2.52%)

REGI

Renewable Energy

$15.90

0.57 (3.72%)

PSX

Phillips 66

$102.77

0.66 (0.65%)

MPC

Marathon Petroleum

$53.29

0.1 (0.19%)

VLO

Valero

$85.53

1.84 (2.20%)

EVA

Enviva

$31.21

0.06 (0.19%)

AMTX

Aemetis

$1.00

0.14 (16.28%)

PEIX

Pacific Ethanol

$0.78

0.0322 (4.29%)

GPP

Green Plains Partners

$13.18

0.17 (1.31%)

DK

Delek US

$35.91

-0.6 (-1.64%)

HFC

HollyFrontier

$51.41

0.71 (1.40%)

TSO

Tesoro

$0.00

(0.00%)

WNR

Western Refining

$0.00

(0.00%)

T

AT&T

$37.90

-0.46 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

GLD

SPDR Gold Shares

$140.19

-1.14 (-0.81%)

17:58
09/13/19
09/13
17:58
09/13/19
17:58
Hot Stocks
SPDR Gold Shares holdings fall to 874.51MT from 880.37MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

, AIMT

Aimmune

$24.66

(0.00%)

17:57
09/13/19
09/13
17:57
09/13/19
17:57
Hot Stocks
Breaking Hot Stocks news story on DBV Technologies, Aimmune »

DBV Technologies falls 2%…

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

AIMT

Aimmune

$24.66

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AIMT

Aimmune

$24.66

(0.00%)

17:55
09/13/19
09/13
17:55
09/13/19
17:55
Hot Stocks
FDA committee votes to support use of Aimmune's Palforzia for peanut allergy »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

ZAYO

Zayo Group

$33.82

-0.05 (-0.15%)

17:39
09/13/19
09/13
17:39
09/13/19
17:39
Hot Stocks
Zayo Group CEO sells 1M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

T

AT&T

$37.90

-0.46 (-1.20%)

, MO

Altria Group

$42.01

-0.77 (-1.80%)

17:38
09/13/19
09/13
17:38
09/13/19
17:38
Periodicals
CNN to longer run Juul ads, Daily Beast reports »

AT&T's (T) CNN…

T

AT&T

$37.90

-0.46 (-1.20%)

MO

Altria Group

$42.01

-0.77 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BAS

Basic Energy

$1.87

-0.08 (-4.10%)

17:34
09/13/19
09/13
17:34
09/13/19
17:34
Hot Stocks
Basic Energy CEO T.M. Patterson to leave company »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

XBIO

Xenetic

$1.61

-0.04 (-2.42%)

17:28
09/13/19
09/13
17:28
09/13/19
17:28
Syndicate
Breaking Syndicate news story on Xenetic »

Xenetic files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$218.71

-4.4 (-1.97%)

, DIS

Disney

$138.00

0.44 (0.32%)

17:22
09/13/19
09/13
17:22
09/13/19
17:22
Hot Stocks
Disney CEO Bob Iger resigns from Apple board of directors »

In a regulatory filing,…

AAPL

Apple

$218.71

-4.4 (-1.97%)

DIS

Disney

$138.00

0.44 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PHG

Philips

$47.79

0.19 (0.40%)

17:21
09/13/19
09/13
17:21
09/13/19
17:21
Hot Stocks
Philips awarded maximum $400M Defense Logistics Agency contract »

Philips has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBSE

NeuBase Therapeutics

$5.70

-0.04 (-0.70%)

17:20
09/13/19
09/13
17:20
09/13/19
17:20
Syndicate
Breaking Syndicate news story on NeuBase Therapeutics »

NeuBase Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$198.82

1.22 (0.62%)

17:17
09/13/19
09/13
17:17
09/13/19
17:17
Hot Stocks
Raytheon awarded $427.3M Army procurement contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

INPX

Inpixon

$0.14

-0.0001 (-0.07%)

17:16
09/13/19
09/13
17:16
09/13/19
17:16
Syndicate
Breaking Syndicate news story on Inpixon »

Inpixon files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$6.59

0.14 (2.17%)

17:14
09/13/19
09/13
17:14
09/13/19
17:14
Syndicate
Aurinia Pharmaceuticals files to sell $40M of common shares at-the-market »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.